Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Adicet Bio Inc ACET

Healthcare Biotechnology
Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the... see more

Recent & Breaking News (NDAQ:ACET)

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 1, 2022

Adicet Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress

Business Wire March 15, 2022

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 4, 2022

Adicet Bio to Participate in Guggenheim 2022 Oncology Conference

Business Wire February 2, 2022

Adicet Bio, Inc. Announces Closing of $100 Million Public Follow-On Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

GlobeNewswire December 10, 2021

Adicet Bio, Inc. Announces Pricing of Public Offering of Common Stock

GlobeNewswire December 8, 2021

Adicet Bio, Inc. Announces Proposed Follow-On Offering of Common Stock

GlobeNewswire December 7, 2021

Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell Therapy

GlobeNewswire December 6, 2021

Adicet Bio to Host Webcast Presentation of ADI-001 Interim Clinical Data in B Cell Non-Hodgkin's Lymphoma

GlobeNewswire November 29, 2021

Adicet Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors

GlobeNewswire November 18, 2021

Adicet Presents Preclinical Data for ADI-002, a GPC3-Targeted Development Candidate for Solid Tumors, at the SITC Annual Meeting

GlobeNewswire November 12, 2021

Adicet Reports Third Quarter 2021 Financial Results and Provides Business Updates

GlobeNewswire November 10, 2021

Adicet Bio to Participate in Stifel 2021 Virtual Healthcare Conference

GlobeNewswire November 8, 2021

Adicet Announces Trials in Progress Poster Presentation for ADI-001 at 2021 ASH Annual Meeting

GlobeNewswire November 4, 2021

Adicet Announces Promotion of Blake Aftab, Ph.D. to Chief Scientific Officer

GlobeNewswire October 12, 2021

Adicet to Present Preclinical Data from Allogeneic Gamma Delta T Cell Platform at SITC 36th Annual Meeting

GlobeNewswire October 4, 2021

Adicet Bio Collaborates with Twist Bioscience to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics

GlobeNewswire September 13, 2021

Twist Bioscience Collaborates with Adicet Bio to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics

Business Wire September 13, 2021

Adicet Bio to Participate in Upcoming Investor Conferences

GlobeNewswire September 2, 2021

Adicet Reports Second Quarter 2021 Financial Results and Provides Business Updates

GlobeNewswire August 12, 2021